Evidence map›Paper›PMID 41333354›Full record

ArticleEcancermedicalscience2025

Association of serum cyclooxygenase-2 levels with hand-foot syndrome in patients receiving capecitabine: an exploratory analysis of D-TORCH study.

Ghazal Tansir, Akhil Santhosh, Akash Kumar, Hemavathi Baskarane, Mohit Kumar Divakar, Vishakha Hooda, Arundhati J R Dev, Chandra Prakash Prasad, Ishaan Gupta, Saran Kumar and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ghazal TansirDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Akhil SanthoshDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Akash KumarDepartment of Medical Oncology, National Cancer Institute, All India Institute of Medical Sciences, Haryana 124105, India.
Hemavathi BaskaraneDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Mohit Kumar DivakarDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Vishakha HoodaDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Arundhati J R DevDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Chandra Prakash PrasadDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Ishaan GuptaDepartment of Biochemical Engineering and Biotechnology, Indian Institute of Technology Delhi, New Delhi 110016, India.
Saran KumarKusuma School of Biological Sciences, Indian Institute of Technology Delhi, New Delhi 110016, India.
Pranay TanwarDepartment of Laboratory Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Atul SharmaDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Sameer BakhshiDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.
Atul BatraDepartment of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi 110029, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The D-TORCH trial demonstrated superiority of 1% topical diclofenac over placebo in preventing capecitabine-induced hand-foot syndrome (HFS). We conducted an exploratory analysis of this study to assess the relationship between HFS and serum levels of the inflammatory marker, cyclooxygenase-2 (COX-2). Methods: Serum COX-2 levels were measured in patients in the D-TORCH study's experimental and placebo arms at baseline and 12 weeks of capecitabine-based therapy or at the development of HFS (whichever occurred earlier) and in 20 age-matched healthy controls using a human COX-2 ELISA kit (E-EL-H5574). Results: 233 (88.5%) patients of the D-TORCH cohort ( Conclusion: Serum COX-2 levels did not show a significant change with capecitabine-based therapy, regardless of the use of topical diclofenac possibly reflecting the predominant stromal production of the enzyme. This finding highlights the need to assess HFS-affected tissues for local COX-2 immuno-expression along with further blood-based biomarkers.

Indexed as

biomarkerscyclooxygenasehand-foot syndromesupportive care

Identifiers

PMID41333354
PMCPMC12665898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.